18-02-2021 дата публикации
Номер: US20210047301A1
Автор:
CHIN Jung-Wook,
JEONG Tae-Cheon,
JUNG Kyung-Jin,
Kim Jun-Woo,
KIM Jung-Ae,
KIM Kyung-Hee,
KIM Shin-Ae,
Lee Eung-Seok,
LEE Ji-Hoon,
LEE Ju-Suk,
Lee Won-Seok,
MIN Sang-Hyun,
SONG Jae-Young,
YU Ji-Hoon
Provided is a 2-cyanopyrimidin-4-yl carbamate or urea derivative or pharmaceutically acceptable salt thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The 2-cyanopyrimidin-4-yl carbamate or urea derivative or pharmaceutically acceptable salt thereof selectively inhibits cathepsin K and therefore can be usefully applied for preventing or treating osteoporosis. 2. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the aromatic ring is optionally substituted with one to three substituents selected from the group consisting of halogen claim 1 , cyano claim 1 , hydroxy claim 1 , trifluoromethyl claim 1 , C˜Calkyl claim 1 , C˜Ccycloalkyl claim 1 , C˜Calkoxy claim 1 , hydroxymethyl claim 1 , methoxymethyl claim 1 , hydroxycarbonylmethyl claim 1 , hydroxycarbonylethyl claim 1 , methoxycarbonylmethyl claim 1 , methoxyethoxymethyl claim 1 , acetylaminomethyl claim 1 , aminoethoxy claim 1 , methylaminoethoxy claim 1 , dimethylaminoethoxy claim 1 , aminosulfonyl claim 1 , methanesulfonyl claim 1 , trifluoromethylsulfonyl claim 1 , cyclopropylaminosulfonyl claim 1 , mono- or di-C˜Calkylamino claim 1 , acetylamino claim 1 , methanesulfonylamino claim 1 , acetyl claim 1 , hydroxycarbonyl claim 1 , dimethylaminocarbonyl claim 1 , oxolanylmethylaminocarbonyl claim 1 , dimethylaminoethylaminocarbonyl claim 1 , imidazolylethylaminocarbonyl claim 1 , methoxyethylaminocarbonyl claim 1 , cyclopropylaminocarbonyl claim 1 , pyrrolidinylcarbonyl claim 1 , triazolylethylaminocarbonyl claim 1 , methoxycarbonylbutynyl claim 1 , hydroxycarbonylbutynyl claim 1 , hydroxymethylphenylethynyl claim 1 , and methoxyethylphenoxymethyl.3. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the aromatic ring is substituted with one or two substituents selected from the group consisting of halogen claim 1 , C˜Calkyl claim 1 , and acetyl.4. The compound or pharmaceutically acceptable ...
Подробнее